• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5084059)   Today's Articles (21)
For: Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24. [PMID: 16757724 DOI: 10.1001/jama.295.21.2516] [Citation(s) in RCA: 945] [Impact Index Per Article: 49.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Number Cited by Other Article(s)
351
Esper P. Concepts in advanced renal carcinoma. Semin Oncol Nurs 2012;28:170-9. [PMID: 22846485 DOI: 10.1016/j.soncn.2012.05.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
352
Barrière J, Hoch B, Ferrero JM. New perspectives in the treatment of metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2012;84 Suppl 1:e16-23. [DOI: 10.1016/j.critrevonc.2011.10.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2011] [Revised: 07/21/2011] [Accepted: 10/19/2011] [Indexed: 01/04/2023]  Open
353
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol 2012. [PMID: 23179639 DOI: 10.1007/s10147-012-0497-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
354
Boysen G, Bausch-Fluck D, Thoma CR, Nowicka AM, Stiehl DP, Cima I, Luu VD, von Teichman A, Hermanns T, Sulser T, Ingold-Heppner B, Fankhauser N, Wenger RH, Krek W, Schraml P, Wollscheid B, Moch H. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia 2012;14:535-46. [PMID: 22806541 DOI: 10.1596/neo.12130] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2012] [Revised: 04/27/2012] [Accepted: 04/30/2012] [Indexed: 01/09/2023]
355
Melichar B, Procházková-Študentová H, Vitásková D. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial. Expert Rev Anticancer Ther 2012;12:1253-61. [PMID: 23136836 DOI: 10.1586/era.12.103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
356
Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts. J Pharmacol Exp Ther 2012;343:509-19. [PMID: 22869928 PMCID: PMC3477209 DOI: 10.1124/jpet.112.196097] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Accepted: 08/03/2012] [Indexed: 01/24/2023]  Open
357
Neri B, Vannini A, Brugia M, Muto A, Rangan S, Rediti M, Tassi R, Cerullo C. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2012;20:478-83. [PMID: 23113655 DOI: 10.1111/j.1442-2042.2012.03204.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 09/23/2012] [Indexed: 11/30/2022]
358
Qiu F, Bian W, Li J, Ge Z. Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2012;27:615-21. [PMID: 23108983 DOI: 10.1002/bmc.2836] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2012] [Revised: 09/28/2012] [Accepted: 09/29/2012] [Indexed: 11/07/2022]
359
Stacchiotti S, Dagrada GP, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, Casali PG. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res 2012;2:22. [PMID: 23058004 PMCID: PMC3534218 DOI: 10.1186/2045-3329-2-22] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Accepted: 09/30/2012] [Indexed: 01/26/2023]  Open
360
Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2012;11:45-50. [PMID: 23041453 DOI: 10.1016/j.clgc.2012.06.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2012] [Revised: 05/17/2012] [Accepted: 06/25/2012] [Indexed: 11/19/2022]
361
Schmidinger M, Larkin J, Ravaud A. Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2012;4:253-65. [PMID: 23024706 DOI: 10.1177/1756287212454933] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
362
Mizuno R, Masuda A, Asanuma H, Miyajima A, Oya M, Karasawa T, Wakino S, Konishi K, Itoh H, Inoue A, Kiyono K, Mikami S, Hashiguchi A, Mukai M, Jinzaki M, Hayashi M. Exacerbation of diabetic nephropathy mimicking thrombotic microangiopathy during sunitinib treatment for metastatic renal cell carcinoma. Int Cancer Conf J 2012. [DOI: 10.1007/s13691-012-0053-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]  Open
363
Peters I, Winkler M, Jüttner B, Teebken OE, Herrmann TR, von Klot C, Kramer M, Reichelt A, Abbas M, Kuczyk MA, Merseburger AS. Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report. World J Urol 2012;32:245-8. [PMID: 23053210 DOI: 10.1007/s00345-012-0955-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Accepted: 09/14/2012] [Indexed: 12/21/2022]  Open
364
Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. ACTA ACUST UNITED AC 2012;19:202-8. [PMID: 22876146 DOI: 10.3747/co.19.972] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
365
Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, Smith RG, LaFleur DW, Barbas CF, Hilbert DM, Kiener PA, Roschke VV. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012;4:600-13. [PMID: 22864384 PMCID: PMC3499301 DOI: 10.4161/mabs.21227] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]  Open
366
De Boer RH, Kotasek D, White S, Koczwara B, Mainwaring P, Chan A, Melara R, Ye Y, Adewoye AH, Sikorski R, Kaufman PA. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2012;135:241-52. [PMID: 22872523 PMCID: PMC3413817 DOI: 10.1007/s10549-012-2135-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2012] [Accepted: 06/08/2012] [Indexed: 01/06/2023]
367
Liu WM, Dalgleish AG. The potential beneficial effects of drugs on the immune response to vaccination. Semin Oncol 2012;39:340-7. [PMID: 22595056 DOI: 10.1053/j.seminoncol.2012.02.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
368
Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Second-line therapy for refractory renal-cell carcinoma. Crit Rev Oncol Hematol 2012;83:112-22. [DOI: 10.1016/j.critrevonc.2011.08.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Revised: 04/26/2011] [Accepted: 08/26/2011] [Indexed: 01/06/2023]  Open
369
Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Senard JM, Pathak A. [Cardiotoxicity of chemotherapies]. Presse Med 2012;42:26-39. [PMID: 22727981 DOI: 10.1016/j.lpm.2012.04.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2011] [Revised: 04/11/2012] [Accepted: 04/12/2012] [Indexed: 12/18/2022]  Open
370
Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, Bagby SP, Kolumam G, Kowalski J, Oyer JA, Bunting S, Lindner JR. Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol 2012;60:618-25. [PMID: 22703929 DOI: 10.1016/j.jacc.2012.02.053] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 02/02/2012] [Accepted: 02/06/2012] [Indexed: 01/01/2023]
371
Fujita T, Iwamura M, Ishii D, Tabata KI, Matsumoto K, Yoshida K, Baba S. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 2012;19:908-13. [DOI: 10.1111/j.1442-2042.2012.03071.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
372
Della Pina P, Vizzardi E, Raddino R, Gavazzoni M, Caretta G, Gorga E, Dei Cas L. Biological Drugs: Classic Adverse Effects and New Clinical Evidences. Cardiovasc Toxicol 2012;12:285-97. [DOI: 10.1007/s12012-012-9173-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
373
Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T, Kikkawa F. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer 2012;22:801-6. [PMID: 22617480 DOI: 10.1097/igc.0b013e3182540145] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
374
Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Urol Oncol 2012;31:1800-5. [PMID: 22658883 DOI: 10.1016/j.urolonc.2012.04.019] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Revised: 04/23/2012] [Accepted: 04/23/2012] [Indexed: 10/28/2022]
375
Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. Cancer Treat Rev 2012;39:230-40. [PMID: 22647546 DOI: 10.1016/j.ctrv.2012.04.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2012] [Revised: 04/18/2012] [Accepted: 04/26/2012] [Indexed: 11/29/2022]
376
Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Doval DC, Strahs A, Slichenmyer WJ, Bhargava P. Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma. J Clin Oncol 2012;30:1678-85. [DOI: 10.1200/jco.2011.35.3524] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
377
An update on targeted therapy in metastatic renal cell carcinoma. Urol Oncol 2012;30:240-6. [DOI: 10.1016/j.urolonc.2009.12.018] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2009] [Revised: 12/19/2009] [Accepted: 12/22/2009] [Indexed: 11/19/2022]
378
Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, Nishimura K, Nonomura N. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Med Oncol 2012;29:3298-305. [PMID: 22544539 DOI: 10.1007/s12032-012-0236-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2012] [Accepted: 04/06/2012] [Indexed: 12/22/2022]
379
Robert C, Sibaud V, Mateus C, Cherpelis BS. Advances in the Management of Cutaneous Toxicities of Targeted Therapies. Semin Oncol 2012;39:227-40. [DOI: 10.1053/j.seminoncol.2012.01.009] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
380
Grenier J. Complications cardiaques et vasculaires des antiangiogéniques (à l’exception des effets rénaux et des complications hémorragiques). ONCOLOGIE 2012. [DOI: 10.1007/s10269-012-2145-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
381
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Med Oncol 2012;29:3003-8. [PMID: 22447483 DOI: 10.1007/s12032-012-0204-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2012] [Accepted: 02/29/2012] [Indexed: 12/13/2022]
382
Négrier S. Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices. Oncology 2012;82:189-96. [PMID: 22440948 DOI: 10.1159/000336888] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Accepted: 01/26/2012] [Indexed: 01/07/2023]
383
Kassem MG, Motiur Rahman AFM, Korashy HM. Sunitinib malate. PROFILES OF DRUG SUBSTANCES, EXCIPIENTS, AND RELATED METHODOLOGY 2012;37:363-388. [PMID: 22469323 DOI: 10.1016/b978-0-12-397220-0.00009-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
384
Vázquez S, León L, Fernández O, Lázaro M, Grande E, Aparicio L. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Ther 2012;29:202-17. [PMID: 22328304 DOI: 10.1007/s12325-011-0099-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Indexed: 10/14/2022]
385
Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model. JOURNAL OF ONCOLOGY 2012;2012:103298. [PMID: 22481916 PMCID: PMC3317372 DOI: 10.1155/2012/103298] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2011] [Accepted: 11/14/2011] [Indexed: 12/16/2022]
386
Maxwell CB, Jenkins AT. Drug-induced heart failure. Am J Health Syst Pharm 2012;68:1791-804. [PMID: 21930637 DOI: 10.2146/ajhp100637] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]  Open
387
Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 2012;30:2066-79. [PMID: 22327313 PMCID: PMC3432793 DOI: 10.1007/s10637-012-9796-8] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2011] [Accepted: 01/20/2012] [Indexed: 12/21/2022]
388
Mitchell L, Thamm D, Biller B. Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer. J Vet Intern Med 2012;26:355-62. [DOI: 10.1111/j.1939-1676.2011.00883.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2011] [Revised: 12/02/2011] [Accepted: 12/19/2011] [Indexed: 12/16/2022]  Open
389
Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. Anticancer Drugs 2012;23:149-54. [DOI: 10.1097/cad.0b013e32834b3fae] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
390
Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012;30:335-40. [PMID: 20711632 PMCID: PMC3257373 DOI: 10.1007/s10637-010-9491-6] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2010] [Accepted: 07/07/2010] [Indexed: 01/24/2023]
391
Tobert CM, Uzzo RG, Wood CG, Lane BR. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology. Urol Oncol 2012;31:1316-20. [PMID: 22264501 DOI: 10.1016/j.urolonc.2011.12.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Revised: 12/19/2011] [Accepted: 12/19/2011] [Indexed: 11/16/2022]
392
Eisengart LJ, MacVicar GR, Yang XJ. Predictors of response to targeted therapy in renal cell carcinoma. Arch Pathol Lab Med 2012;136:490-5. [PMID: 22229848 DOI: 10.5858/arpa.2010-0308-ra] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
393
Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 2012;795:1-34. [PMID: 21960212 DOI: 10.1007/978-1-61779-337-0_1] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
394
Sadeghi S, Rini B. Angiogenesis Inhibitor Therapy in Renal Cell Cancer. KIDNEY CANCER 2012. [DOI: 10.1007/978-3-642-21858-3_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
395
Combinatorial and Sequential Targeted Therapy in Metastatic Renal Cell Carcinoma. KIDNEY CANCER 2012. [DOI: 10.1007/978-3-642-21858-3_15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
396
Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsanious A, Plotkin A, Girgis AHF, Streutker CJ, Yousef GM. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. J Transl Med 2012;92:46-56. [PMID: 22042086 DOI: 10.1038/labinvest.2011.153] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]  Open
397
Kollmannsberger C, Bjarnason GA, Ravaud A. Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. KIDNEY CANCER 2012. [DOI: 10.1007/978-3-642-21858-3_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
398
Morizane S, Iwamoto H, Yao A, Isoyama T, Sejima T, Takenaka A. A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib. Cent European J Urol 2012;65:227-9. [PMID: 24578969 PMCID: PMC3921806 DOI: 10.5173/ceju.2012.04.art11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2012] [Revised: 05/20/2012] [Accepted: 05/25/2012] [Indexed: 11/25/2022]  Open
399
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. ACTA ACUST UNITED AC 2011;31:799-806. [PMID: 22173502 DOI: 10.1007/s11596-011-0680-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Indexed: 01/29/2023]
400
Smaldone MC, Fung C, Uzzo RG, Haas NB. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:765-91. [PMID: 21763967 DOI: 10.1016/j.hoc.2011.06.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
PrevPage 8 of 19 127891819Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA